These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 8996752)

  • 1. OKT3 induction therapy: influence of duration on rejections and infections.
    Zibari GB; Boykin KN; Thomas JP; Aultman DF; Aradhye SA; McMillan RW; McDonald JC
    Clin Transplant; 1996 Dec; 10(6 Pt 2):614-6. PubMed ID: 8996752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of induction therapy on rejection and survival in heart transplantation.
    Almenar L; García-Palomar C; Martínez-Dolz L; Chamorro C; Moro J; Zorio E; Arnau MA; Rueda J; Osa A; Cardo ML
    Transplant Proc; 2005 Nov; 37(9):4024-7. PubMed ID: 16386616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation.
    Cuppoletti A; Perez-Villa F; Vallejos I; Roig E
    Transplant Proc; 2005 Nov; 37(9):4036-8. PubMed ID: 16386620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two low-dose OKT3 induction regimens following renal transplantation--clinical experience at a single center.
    Oh HK; Provenzano R; Tayeb J; Satmary N; Jones B
    Clin Transplant; 1998 Aug; 12(4):343-7. PubMed ID: 9686329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction versus noninduction therapy in kidney transplantation: considering different PRA levels and different induction therapies.
    Castro MC; Araujo LM; Nahas WC; Arap S; David-Neto E; Ianhez LE
    Transplant Proc; 2004 May; 36(4):874-6. PubMed ID: 15194299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
    Emre S; Gondolesi G; Polat K; Ben-Haim M; Artis T; Fishbein TM; Sheiner PA; Kim-Schluger L; Schwartz ME; Miller CM
    Liver Transpl; 2001 Mar; 7(3):220-5. PubMed ID: 11244163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of first acute rejection episode and severity of rejection on cadaveric renal allograft survival.
    Hariharan S; Alexander JW; Schroeder TJ; First MR
    Clin Transplant; 1996 Dec; 10(6 Pt 1):538-41. PubMed ID: 8996775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of HLA matching on survival in heart transplantation.
    Almenar L; Maeso ML; Martínez-Dolz L; Rueda J; Palomar CG; Sáez AO; Vives MA; Tort MD; Pérez MP
    Transplant Proc; 2005 Nov; 37(9):4001-5. PubMed ID: 16386610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy?
    Higgins R; Kirklin JK; Brown RN; Rayburn BK; Wagoner L; Oren R; Miller L; Flattery M; Bourge RC;
    J Heart Lung Transplant; 2005 Apr; 24(4):392-400. PubMed ID: 15797738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
    Rosen HR; Shackleton CR; Higa L; Gralnek IM; Farmer DA; McDiarmid SV; Holt C; Lewin KJ; Busuttil RW; Martin P
    Am J Gastroenterol; 1997 Sep; 92(9):1453-7. PubMed ID: 9317061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
    Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
    Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OKT3 treatment of cardiac allograft rejection.
    Haverty TP; Sanders M; Sheahan M
    J Heart Lung Transplant; 1993; 12(4):591-8. PubMed ID: 8369321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OKT3 rescue therapy for 63 refractory rejections in 405 renal allografts.
    Uchida K; Namii Y; Tominaga Y; Haba T; Tanaka H; Ichimori T; Uemura O; Morozumi K; Hayashi S; Yokoyama J; Takagi H
    Transplant Proc; 1996 Jun; 28(3):1358-9. PubMed ID: 8658693
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
    Cantarovich M; Latter DA; Loertscher R
    Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The UNOS Scientific Renal Transplant Registry.
    Cecka JM
    Clin Transpl; 1999; ():1-21. PubMed ID: 11038622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal graft survival in children with early acute rejection.
    Muñoz R; Romero B; Medeiros M; Zaragoza L
    Pediatr Transplant; 1998 Nov; 2(4):294-8. PubMed ID: 10084732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [OKT3 treatment of refractory renal allograft rejection].
    Xu J; Ma J; Bai X
    Zhonghua Wai Ke Za Zhi; 1997 Apr; 35(4):223-5. PubMed ID: 10374543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate or total lymphoid radiation for treatment of persistent or recurrent allograft cellular rejection: a comparative study.
    Ross HJ; Gullestad L; Pak J; Slauson S; Valantine HA; Hunt SA
    J Heart Lung Transplant; 1997 Feb; 16(2):179-89. PubMed ID: 9059929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.